BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei S, Yang M, Geng X, Xiong Q, Hou H, Zhou D, Cui X. Prognostic factors in hepatocellular carcinoma patients with Child-Pugh A liver function after hepatectomy: Not related to the surgical approach. Ann Hepatol 2021;:100580. [PMID: 34788657 DOI: 10.1016/j.aohep.2021.100580] [Reference Citation Analysis]
2 Ren D, Li J, Zhou B, Guo S, Guo B. Modelling of the Dynamics of Vascular Embolization by Using Porous Media for the Design of Injection Robots of Embolic Agents. Medical Engineering & Physics 2022. [DOI: 10.1016/j.medengphy.2022.103774] [Reference Citation Analysis]
3 Zhang M, Zhao H, Gao H. Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Viral Immunology. [DOI: 10.1089/vim.2021.0174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
6 Liu J, Li Z, Zhang W, Lu H, Sun Z, Wang G, Han X. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Front Pharmacol 2021;12:709060. [PMID: 34733154 DOI: 10.3389/fphar.2021.709060] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu X, Guo R, Tian J. Association of Plasma Fibrinogen Levels on Postoperative Day 1 with 2-Year Survival of Orthotopic Liver Transplantation for HBV-Related HCC. Lab Med 2021:lmab052. [PMID: 34268570 DOI: 10.1093/labmed/lmab052] [Reference Citation Analysis]
8 Yan J, Li T, Deng M, Fan H. Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know? Front Oncol 2022;12:927123. [DOI: 10.3389/fonc.2022.927123] [Reference Citation Analysis]
9 Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. Int J Mol Sci 2021;22:12880. [PMID: 34884684 DOI: 10.3390/ijms222312880] [Reference Citation Analysis]
10 Xu M, Ma T, Shi S, Xing J, Xi Y. Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. Life (Basel) 2021;11:1312. [PMID: 34947843 DOI: 10.3390/life11121312] [Reference Citation Analysis]
11 Wu MN, Zheng WJ, Ye WX, Wang L, Chen Y, Yang J, Yao DF, Yao M. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth. World J Gastroenterol 2021; 27(23): 3327-3341 [PMID: 34163115 DOI: 10.3748/wjg.v27.i23.3327] [Reference Citation Analysis]
12 Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021;27:8069-80. [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] [Reference Citation Analysis]
13 Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, Cao Z, Ren S, Ma L, Jin Y, Zheng S, Hu Z, Wang L, Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med 2021;9:1365. [PMID: 34733917 DOI: 10.21037/atm-21-1666] [Reference Citation Analysis]
14 Wen C, Tang J, Luo H. Development and Validation of a Nomogram to Predict Cancer-Specific Survival for Middle-Aged Patients With Early-Stage Hepatocellular Carcinoma. Front Public Health 2022;10:848716. [DOI: 10.3389/fpubh.2022.848716] [Reference Citation Analysis]
15 Xu H, Xiong C, Chen Y, Zhang C, Bai D. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered 2021;12:2664-75. [PMID: 34115569 DOI: 10.1080/21655979.2021.1938470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Chen QF, Dai L, Wu Y, Huang Z, Chen M, Zhao M. Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. Front Bioeng Biotechnol 2021;9:667641. [PMID: 34540812 DOI: 10.3389/fbioe.2021.667641] [Reference Citation Analysis]
17 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
18 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
19 Jiang H, Yuan F, Zhao Z, Xue T, Ge N, Ren Z, Zhang L. Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma. Int J Gen Med 2021;14:9145-52. [PMID: 34880653 DOI: 10.2147/IJGM.S334378] [Reference Citation Analysis]
20 Zhang Y, Lv X, Qiu J, Zhang B, Zhang L, Fang J, Li M, Chen L, Wang F, Liu S, Zhang S. Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma. J Magn Reson Imaging 2021;54:134-43. [PMID: 33559293 DOI: 10.1002/jmri.27538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Darwish NM, Elshaer MMA, Almutairi SM, Chen TW, Mohamed MO, Ghaly WBA, Rasheed RA. Omega-3 Polyunsaturated Fatty Acids Provoke Apoptosis in Hepatocellular Carcinoma through Knocking Down the STAT3 Activated Signaling Pathway: In Vivo and In Vitro Study. Molecules 2022;27:3032. [PMID: 35566382 DOI: 10.3390/molecules27093032] [Reference Citation Analysis]
22 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
23 Yao J, Liu B, Wang X, Yu J, Cheng Z, Han Z, Liu F, Zheng R, Cheng W, Wei Q, Yu S, Li K, Chen P, Luo Y, Yu X, Liang P. Long-term efficacy of microwave ablation in the treatment of subcapsular hepatocellular carcinomas of ≤3 cm in diameter: a multicenter, propensity score-matched study. International Journal of Hyperthermia 2022;39:209-16. [DOI: 10.1080/02656736.2021.2023228] [Reference Citation Analysis]
24 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang X, Wang Z, Tang W, Wang X, Liu R, Bao H, Chen X, Wei Y, Wu S, Bao H, Wu X, Shao Y, Fan J, Zhou J. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology 2021. [PMID: 34954829 DOI: 10.1002/hep.32308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Qi W, Shen J, Dai J, Wu Y, Zhang Y, Leng S, Gao F, Ran S, Peng W, Zhang X, Wen T, Li C. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study. Cancer Med 2021. [PMID: 34643050 DOI: 10.1002/cam4.4348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Jin ZC, Chen L, Zhong BY, Zhu HD, Zeng CH, Li R, Guo JH, He SC, Deng G, Zhu XL, Ni CF, Teng GJ. Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:602700. [PMID: 34026598 DOI: 10.3389/fonc.2021.602700] [Reference Citation Analysis]
28 Ding DY, Liu L, Li HL, Gan XJ, Ding WB, Gu FM, Sun DP, Li W, Pan ZY, Yuan SX, Zhou WP. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00052-2. [PMID: 35428596 DOI: 10.1016/j.hbpd.2022.04.002] [Reference Citation Analysis]
29 Liu F, Guo X, Dong W, Zhang W, Wei S, Zhang S, Zhu X, Zhou W, Zhang J, Liu H. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection. Int J Biol Sci 2020;16:3210-20. [PMID: 33162826 DOI: 10.7150/ijbs.46896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wang F, Zhu L, Xue Q, Tang C, Tang W, Zhang N, Dai C, Chen Z. Novel lncRNA AL033381.2 Promotes Hepatocellular Carcinoma Progression by Upregulating PRKRA Expression. Oxid Med Cell Longev 2022;2022:1125932. [PMID: 35035655 DOI: 10.1155/2022/1125932] [Reference Citation Analysis]
31 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
32 Sun HC, Zhu XD. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Front Oncol 2021;11:772195. [PMID: 34869008 DOI: 10.3389/fonc.2021.772195] [Reference Citation Analysis]
33 Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Reference Citation Analysis]
34 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
35 Tian Y, Wang J, Tian G, Li B, Chen M, Sun X. Long Non-Coding RNA MAFG-AS1 as a Potential Biomarker for Hepatocellular Carcinoma: Linkage with Tumor Features, Markers, Liver Functions, and Survival Profile. Front Surg 2022;9:848831. [DOI: 10.3389/fsurg.2022.848831] [Reference Citation Analysis]
36 Chen J, Zhang J, Zhang Z. Upregulation of GTPBP4 Promotes the Proliferation of Liver Cancer Cells. J Oncol 2021;2021:1049104. [PMID: 34712323 DOI: 10.1155/2021/1049104] [Reference Citation Analysis]
37 Bo J, Beining K, Xiang F, Xinkun W, Yukun L. Discrepancy of contrast-enhanced ultrasonographic pattern with two contrast agents in steatohepatitic subtype hepatocellular carcinoma: A case report. Radiology Case Reports 2022;17:1905-10. [DOI: 10.1016/j.radcr.2022.03.010] [Reference Citation Analysis]
38 Sheng X, Zhou J, Gu X, Wang H, Li C. The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/3451544] [Reference Citation Analysis]
39 Li Y, Shimizu S, Mizumoto M, Iizumi T, Numajiri H, Makishima H, Li G, Sakurai H. Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation. Cureus. [DOI: 10.7759/cureus.25744] [Reference Citation Analysis]
40 Li N, Wan X, Zhang H, Zhang Z, Guo Y, Hong D. Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection. BMC Cancer 2022;22:664. [PMID: 35715783 DOI: 10.1186/s12885-022-09743-6] [Reference Citation Analysis]
41 Zhang ZY, Zhang EL, Zhang BX, Chen XP, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World J Gastrointest Surg 2021; 13(8): 796-805 [PMID: 34512903 DOI: 10.4240/wjgs.v13.i8.796] [Reference Citation Analysis]
42 Lu F, Ma XJ, Jin WL, Luo Y, Li X. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges. Front Immunol 2021;12:690565. [PMID: 34054880 DOI: 10.3389/fimmu.2021.690565] [Reference Citation Analysis]
43 Liao M, Wang C, Zhang B, Jiang Q, Liu J, Liao J. Distinguishing Hepatocellular Carcinoma From Hepatic Inflammatory Pseudotumor Using a Nomogram Based on Contrast-Enhanced Ultrasound. Front Oncol 2021;11:737099. [PMID: 34692513 DOI: 10.3389/fonc.2021.737099] [Reference Citation Analysis]
44 Liu YH, Fan ZH, Yin SS, Yan K, Sun LQ, Jiang BB. Diagnostic value of color parametric imaging and contrast-enhanced ultrasound in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Clin Ultrasound 2022. [PMID: 35084048 DOI: 10.1002/jcu.23138] [Reference Citation Analysis]
45 Chen QF, Liu S, Lyu N, Jia Z, Chen M, Zhao M. Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. J Vasc Interv Radiol 2021;32:1548-1557.e2. [PMID: 34474127 DOI: 10.1016/j.jvir.2021.07.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Liao S, Wang K, Zhang L, Shi G, Wang Z, Chen Z, Zhu P, He Q. PRC1 and RACGAP1 are Diagnostic Biomarkers of Early HCC and PRC1 Drives Self-Renewal of Liver Cancer Stem Cells. Front Cell Dev Biol 2022;10:864051. [PMID: 35445033 DOI: 10.3389/fcell.2022.864051] [Reference Citation Analysis]
47 Zhang Z, Wu Y, Lin N, Yin S, Meng Z. Monitoring Clinical-Pathological Grading of Hepatocellular Carcinoma Using MicroRNA-Guided Semiconducting Polymer Dots. ACS Appl Mater Interfaces 2022. [PMID: 35112844 DOI: 10.1021/acsami.1c24191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dai L, Cai X, Mugaanyi J, Liu Y, Mao S, Lu C, Lu C. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci Rep 2021;11:19711. [PMID: 34611195 DOI: 10.1038/s41598-021-98937-2] [Reference Citation Analysis]
49 Xu G, Xu WY, Xiao Y, Jin B, Du SD, Mao YL, Zhang ZT. The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma. Cancer Cell Int 2020;20:496. [PMID: 33061848 DOI: 10.1186/s12935-020-01581-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann Transl Med 2021;9:1412. [PMID: 34733964 DOI: 10.21037/atm-21-3020] [Reference Citation Analysis]
51 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
53 Lv B, Liu X, Zhu X, Huang M. miR-382-5p promotes cell invasion in hepatocellular carcinoma by targeting PTEN to activate PI3K/Akt signaling pathway. World J Surg Oncol 2022;20:175. [PMID: 35655254 DOI: 10.1186/s12957-022-02638-7] [Reference Citation Analysis]
54 Long H, Xu W, Zhong X, Chen Z, Su L, Duan Y, Shi Y, Xie X, Lin M. Feasibility of liver stiffness measured using two-dimensional shear wave elastography in assessing preoperative liver function for patients with hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:664-71. [PMID: 34914008 DOI: 10.1007/s00261-021-03374-4] [Reference Citation Analysis]
55 Shi Z, Yang W, Tang H, Li X. Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25851. [PMID: 34011050 DOI: 10.1097/MD.0000000000025851] [Reference Citation Analysis]
56 Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, Chen H, Wu D, Yang R, Wang K, Liu W, Wang H, Bao Q, Liu M, Hao C, Shen L, Xing B, Wang X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology 2022;:211545. [PMID: 35103539 DOI: 10.1148/radiol.211545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yang L, Hou J, Han E, Qiao G, Liu L, Men X. Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis. Int J Pept Res Ther 2021;27:1229-37. [DOI: 10.1007/s10989-021-10163-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria. Clin Res Hepatol Gastroenterol 2022;:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
61 Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021;21:401. [PMID: 33849479 DOI: 10.1186/s12885-021-08138-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Liu S, Liu KC, Lv WF, Lu D, Zhu XH, Jiang B, Tan YL, Wang GX. The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:774345. [PMID: 34970563 DOI: 10.3389/fmed.2021.774345] [Reference Citation Analysis]
63 Liu XF, Zhu XD, Feng LH, Li XL, Xu B, Li KS, Xiao N, Lei M, Sun HC, Tang ZY. Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Exp Hematol Oncol 2022;11:20. [PMID: 35379324 DOI: 10.1186/s40164-022-00275-0] [Reference Citation Analysis]
64 Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Li Z, Han N, Ren X, Zhang Y, Chu X. Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study. Front Oncol 2022;12:833884. [PMID: 35433466 DOI: 10.3389/fonc.2022.833884] [Reference Citation Analysis]
66 Fang Y, Yan D, Wang L, Zhang J, He Q. Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma. J Clin Lab Anal 2022;:e24541. [PMID: 35666610 DOI: 10.1002/jcla.24541] [Reference Citation Analysis]
67 Wang Y, Zhou C, Liu J, Shi Q, Huang S, Yang C, Li T, Chen Y, Xiong B. Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6935-41. [PMID: 34522136 DOI: 10.2147/CMAR.S328812] [Reference Citation Analysis]
68 Liao R, Wei X, Che P, Yin K, Liu L. Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection. Front Oncol 2022;11:755920. [DOI: 10.3389/fonc.2021.755920] [Reference Citation Analysis]
69 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
70 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
71 Xiong KG, Ke KY, Chen LF, Kong JF, Lin TS, Lin QB, Lin S, Zhu YY. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00051-0. [PMID: 35466065 DOI: 10.1016/j.hbpd.2022.04.001] [Reference Citation Analysis]
72 Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Front Oncol 2022;12:809709. [PMID: 35280760 DOI: 10.3389/fonc.2022.809709] [Reference Citation Analysis]
73 Jiang Y, Cai D, Shi S. Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. CLEP 2022;Volume 14:581-90. [DOI: 10.2147/clep.s352045] [Reference Citation Analysis]
74 Wang H, He X, Fang D, Wang X, Guan J, Shi Z, Chen X. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clinics and Research in Hepatology and Gastroenterology 2021. [DOI: 10.1016/j.clinre.2021.101853] [Reference Citation Analysis]
75 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Lu HZ, Mai RY, Wang XB, Chen J, Bai T, Ma L, Xiang BD, Cheng SQ, Guo WX, Li LQ, Ye JZ. Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension. Future Oncol 2022;18:2683-94. [PMID: 35699041 DOI: 10.2217/fon-2021-1297] [Reference Citation Analysis]
77 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
78 Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Reference Citation Analysis]
79 Liang X, Liangliang X, Peng W, Tao Y, Jinfu Z, Ming Z, Mingqing X. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients. Sci Rep 2021;11:14624. [PMID: 34272447 DOI: 10.1038/s41598-021-94035-5] [Reference Citation Analysis]
80 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
81 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Al-Ameri A, Yu X, Zheng S. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis. Transplant Rev (Orlando) 2021;36:100676. [PMID: 34999555 DOI: 10.1016/j.trre.2021.100676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Liao K, Yang K, Cao L, Lu Y, Zheng B, Li X, Wang X, Li J, Chen J, Zheng S. Laparoscopic Anatomical Versus Non-anatomical hepatectomy in the Treatment of Hepatocellular Carcinoma: A randomised controlled trial. Int J Surg 2022;:106652. [PMID: 35525414 DOI: 10.1016/j.ijsu.2022.106652] [Reference Citation Analysis]
85 Gao X, Zhao C, Zhang N, Cui X, Ren Y, Su C, Wu S, Yao Z, Yang J. Genetic expression and mutational profile analysis in different pathologic stages of hepatocellular carcinoma patients. BMC Cancer 2021;21:786. [PMID: 34238242 DOI: 10.1186/s12885-021-08442-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Li X, Zhang X, Li Z, Xie C, Qin S, Yan M, Ke Q, Jin X, Lin T, Zhou M, Liang W, Qi Z, Geng Z, Quan X. Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2021;11:688087. [PMID: 34540664 DOI: 10.3389/fonc.2021.688087] [Reference Citation Analysis]
87 Bian J, Long J, Yang X, Yang X, Xu Y, Lu X, Guan M, Sang X, Zhao H. Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Ann Transl Med 2021;9:765. [PMID: 34268378 DOI: 10.21037/atm-20-7101] [Reference Citation Analysis]